A review of the safety of biosimilar DMARDs during pregnancy reveals critical evidence gaps and the need for informed clinical guidance.

SAN DIEGO — Disease-modifying antirheumatic drugs (DMARDs) and biologics were linked to as much as a 74.5% reduction in the risk for alopecia areata (AA) in patients with psoriasis, a new ...

Editor's note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. The answer, I would say, overwhelmingly is ...

Therapeutic drug monitoring (TDM) — the practice of using laboratory testing to measure blood levels of drugs — has garnered growing interest among rheumatologists in managing patients on ...

Please provide your email address to receive an email when new articles are posted on . Patients with RA who responded to DMARD therapy showed reduced microbiome levels of certain bacteria. DMARD ...

Out of those 688 PsA pregnancies, 54 ended in preterm birth (defined as earlier than gestational week 37), for a rate of 7.8%. Among controls, the rate was 4.5%. Some 85% of preterm births were ...

The global rheumatoid arthritis drugs market was valued at US$31.27 billion in 2024 and is projected to reach US$56.62 billion by 2033, growing at a CAGR of 6.8%. Increased awareness of RA and its ...

A cross-sectional study finds that patients with rheumatoid arthritis receiving disease-modifying antirheumatic drugs (DMARDs) exhibit a reduced immune response to the COVID-19 vaccine compared with ...

Compared with SNRA, SPRA was linked to a 29% higher risk of pneumonia and a 58% higher risk of hospitalization. Researchers noted that seropositivity may reflect greater systemic inflammation and ...